Wockhardt, Jemincare partner for novel respiratory antibiotic Nafithromycin

Wockhardt

Wockhardt Bio AG – a subsidiary of Wockhardt and Jiangxi Jemincare Group Company Limited, China (Jemincare), have partnered for Wockhardt’s novel patented antibiotic WCK 4873 in People’s Republic of China, Hong Kong, Macau and Taiwan for the treatment of community-acquired bacterial pneumonia and other respiratory tract infections.

Wockhardt was quoting at Rs 458.70, up Rs 22.10, or 5.06 percent on the BSE.

News Source:- Moneycontrol

For Enquiry Fill The Form

    *Note:- Please provide a valid Email Id to receive OTP from bigprofitbuzz.com.

    Facebook Iconfacebook like buttonYouTube IconTwitter Icontwitter follow button